Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Another Phase I trial (NCT04629404) was conducted on early-stage PD patients to assess pharmacokinetics, pharmacodynamics, and safety of LY03003, demonstrating well tolerability and promising pharmacodynamic effects, suggesting its suitability for continuous dopaminergic stimulation 141
Whether it is the right fit depends on whether the compounding pharmacy discloses its licensure and PCAB accreditation, whether your prescribing clinician is licensed in your state, and whether you are comfortable with non-FDA-approved compounded product
These tend to follow same pattern of appearing during dose escalation and improving over time
In more basic terms youll hear more patients say its skin sensitivity, a mild burning/tingling sensation, sensitivity to certain fabrics or temperatures on their skin
